0001493152-26-006311
SEC filingIntelligent Bio Solutions Inc. (INBS) reported Q2 2026 results for the period ending December 31, 2025, with revenue of $897K and gross profit of $460K, reflecting a gross margin of approximately 51.3%. The company posted a net loss of $2.7M and comprehensive loss attributable to INBS of $2.7M, or -$3 per basic and diluted share, based on weighted average shares of 951K. Operating expenses totaled $3.2M, driven by $2.3M in selling, general, and administrative costs and $522K in development expenses, resulting in a $2.6M operating loss. Other expenses included $56K interest expense, partially offset by $5K interest income and $73K government support. Balance sheet shows total assets of $17.7M, including $740K cash, $9.4M subscription receivable, and $12.2M current assets, against $6.8M liabilities and $10.9M total equity. Cash flow from operations was -$4.4M, offset by $4.2M financing inflows from $3.3M warrant exercises and $899K stock issuance, yielding a net cash decrease of $280K to $740K end-period (prior $1.0M). No prior period figures disclosed for QoQ comparisons. The $9.4M subscription receivable signals potential liquidity boost upon collection, amid ongoing R&D and regulatory efforts.
Intelligent Bio Solutions Inc. reported for the quarter ended December 31, 2025: revenue of $897K, cost of revenue $437K, yielding gross profit $460K. Total operating expenses reached $3.2M, including $2.3M selling, general and administrative, $522K development and regulatory, $282K depreciation and amortization, and $27K asset impairment, driving a $2.6M loss from operations. Other items included $73K government support income, $56K interest expense, -$801 realized foreign exchange loss, and $5K interest income, netting -$51K other expense. Net loss was $2.7M attributable to INBS, or -$3 per basic/diluted share on 951K weighted average shares. Comprehensive loss mirrored at -$2.7M after $13K foreign currency translation gain. Balance sheet: total assets $17.7M, liabilities $6.8M, equity $10.9M. No prior quarter figures provided for direct QoQ comparison.
Revenue totaled $897K with cost of revenue $437K. No segment breakdown, geographic mix, or growth drivers disclosed in the filing. Government support income of $73K noted separately. Gross profit $460K. Absent prior period data, no growth rates available.
Gross margin approximately 51.3% ($460K / $897K). Operating margin negative at approximately -290% due to $3.2M expenses on $897K revenue. Key cost pressures: $2.3M SG&A (256% of revenue), $522K development. Depreciation $282K, impairment $27K. No prior period margins for trend comparison. Loss from operations -$2.6M.
Net cash used in operating activities -$4.4M, adjusted from -$2.7M net loss by $585K depreciation, $289K impairment, $214K stock compensation, offset by working capital changes like -$522K accounts payable, -$347K other assets. Investing: -$98K ( -$139K property purchases + $40K asset sales). Financing: +$4.2M ($3.3M warrants, $899K stock). Net cash decrease -$280K; ending cash $740K (prior $1.0M). Liquidity: $12.2M current assets vs $5.1M current liabilities. Notable $9.4M subscription receivable, $4.3M payables. No debt beyond minor $13K notes payable.
No management guidance, strategic priorities, or risk factors explicitly disclosed in the provided filing content.